Drugs / LV009 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07284927 | Dec 2025 → Dec 2026 expected | acute lymphoblastic leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV009 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284927 ↗ |
| Route | Intravenous | “Eligible subjects who pass the screening process after providing signed informed consent will receive an infusion of LV009 Injection.” NCT07284927 ↗ |